Clinical Trials Market

The clinical trials industry is presently a market worth more than USD 72.7 Bn and will possibly reach near USD 126.2 Bn by the end of 2033. Through the years of forecast, the market valuation is poised for more than 8% expansion.

The growth of the global clinical trials market is driven by increased research and development activities in pharmaceutical and biotechnology companies, rising prevalence of chronic diseases, demand for personalized medicine, regulatory reforms to expedite drug approvals, and the expansion of clinical trials in emerging markets.

Data analytics and AI are increasingly important in clinical trials. These technologies tend to help in patient recruitment, identifying suitable trial sites, optimising trial designs, and analysing large datasets. AI can predict patient outcomes, detect safety issues, and improve decision-making, leading to more efficient and cost-effective clinical trials.

Patient-centricity is gaining prominence as it involves actively involving patients in the trial process. This approach enhances patient engagement and retention, leading to better data quality and faster trial completion. It also helps in designing trials that better align with patients' needs and preferences.

Some of the biggest names in the clinical trials market include companies like Pfizer, Sanofi SA, Thermo Fisher Scientific Inc., Medpace Holdings, Inc., and Eli Lilly and Company.